A 2007 study in Talanta applied electrospray ionisation mass spectrometry to clarify the mechanism by which the Cu(II) complex transports across membrane interfaces (PMID 19071668)
Who Should Avoid It Known copper sensitivity or Wilson's disease Active skin infections at application site Pregnancy or breastfeeding (injectable) Stop Right Away If You Notice Severe skin irritation, burning, or persistent redness Allergic reactions (rash, swelling, difficulty breathing) Unusual skin discoloration or staining Persistent metallic taste (injectable) Worsening of skin condition after 4-6 weeks Milder Signs to Watch For How Long Should a GHK-Cu Cycle Last
Topical GHK-Cu has been studied for its wide-ranging effects on skin appearance and health
The headline findings: Weight loss matched GLP-1 comparators in both species at sufficiently high dose Tolerability was substantially better markedly less nausea, vomiting, and food aversion Mechanism centers on energy expenditure rather than appetite suppression, via glucagon receptor activation in the liver and adipose tissue and GIP-mediated effects on adipocyte function GLP-1 absence avoided the gut-brain nausea axis that drives the dropout rate of approved drugs The provocation: if you can get tirzepatide-level weight loss without the GLP-1 arm, why include it
BPC-157 + TB-500 (10mg) is currently in stock at Aussie Peptides and available for domestic dispatch across Australia